Tech Company Financing Transactions
Elixir Pharmaceuticals Funding Round
Elixir Pharmaceuticals, operating out of Cambridge, secured $46 million from MPM Capital, Arch Venture Partners and CDIB Bioscience.
Transaction Overview
Company Name
Announced On
11/29/2006
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$46,000,000
Round
Series C
Investors
MPM Capital (Lead Investor) (Ansbert Gaedcke)
Proceeds Purpose
The Series C funds will be used to support:
clinical and regulatory activities supporting a US registration for Glufast®, a small molecule for the treatment of Type 2 diabetes
pre-clinical activities to support an IND filing for EX-1314, a small molecule ghrelin agonist for a variety of metabolic disorders
lead-optimization and IND-enabling pre-clinical studies for a small molecule ghrelin antagonist for the treatment of Type 2 diabetes and obesity
research and discovery efforts focused on a number of novel targets in aging and metabolism, for example
-- SIR T: where Elixir holds a substantial IP position with
novel composition of matter, broad utility claims, and
proprietary know-how and experience
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
300 Putnam Avenue
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Elixir Pharmaceuticals is a genomics-based drug discovery company developing a new category of pharmaceuticals that treat and/or prevent the broad spectrum of diseases that accompany aging.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Medical Officer
Paul Martha
Chief Scientific Officer
Peter DiStefano
VP - Finance
Karen Roberts
Browse more venture capital transactions:
Prev: 11/29/2006: Syndero venture capital transaction
Next: 11/29/2006: VPIsystems venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs